Intellia Therapeutics (NTLA) Leases (2019 - 2026)

Intellia Therapeutics (NTLA) has 8 years of Leases data on file, last reported at $97.5 million in Q1 2026.

• Quarterly Leases fell 29.31% year-over-year to $97.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $97.5 million (down 29.31% YoY) and the FY2025 annual result came in at $106.0 million, down 51.68% from the prior year.
• Leases fell to $97.5 million in Q1 2026 per NTLA's latest filing, from $106.0 million in the prior quarter.
• Across five years, Leases topped out at $219.3 million in Q4 2024 and bottomed at $73.8 million in Q2 2022.
• The 5-year median for Leases is $115.4 million (2023), against an average of $117.3 million.
• The widest annual swing landed in 2022, when Leases jumped 5169.64%; it then slumped 51.68% in 2025.
• Tracing NTLA's Leases over 5 years: stood at $133.1 million in 2022, then decreased by 13.3% to $115.4 million in 2023, then soared by 90.07% to $219.3 million in 2024, then tumbled by 51.68% to $106.0 million in 2025, then declined by 7.94% to $97.5 million in 2026.
• Per Business Quant, the three latest NTLA Leases figures stand at $97.5 million (Q1 2026), $106.0 million (Q4 2025), and $117.9 million (Q3 2025).

Peer Comparison